Trial
NCT03517722
A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Lupus Erythematosus, Systemic
Intervention
Placebo
Why stopped
Study terminated early as a result of the outcome of the pre-planned Interim Analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-29